Woodline Partners’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.81M Buy
153,886
+78
+0.1% +$3.66K 0.01% 721
2026
Q2
$8.25M Sell
153,808
-37,000
-19% -$1.64M 0.03% 577
2026
Q1
$9.2M Buy
190,808
+66,906
+54% +$4.58M 0.03% 531
2025
Q4
$8.62M Buy
123,902
+58,462
+89% +$2.39M 0.03% 496
2025
Q3
$1.83M Sell
65,440
-111,013
-63% -$2.21M 0.01% 737
2025
Q2
$3.66M Buy
176,453
+1,029
+0.6% +$22.6K 0.02% 617
2025
Q1
$3.04M Sell
175,424
-158,477
-47% -$3.88M 0.02% 605
2024
Q4
$9.06M Buy
333,901
+2,328
+0.7% +$82.6K 0.06% 368
2024
Q3
$14.6M Sell
331,573
-5,828
-2% -$225K 0.12% 233
2024
Q2
$13.2M Buy
337,401
+157,509
+88% +$6.47M 0.13% 218
2024
Q1
$7.71M Buy
179,892
+673
+0.4% +$28.4K 0.07% 306
2023
Q4
$7.3M Buy
179,219
+9,219
+5% +$528K 0.08% 265
2023
Q3
$8.57M Hold
170,000
– – 0.1% 243
2023
Q2
$7.07M Hold
170,000
– – 0.08% 253
2023
Q1
$4.04M Buy
+170,000
New +$3.99M 0.06% 321

Other funds holding GPCR

Woodline Partners's GPCR Position: Q3 2026 in Review

Woodline Partners increased its Structure Therapeutics (GPCR) stake by 0.05% in Q3 2026, buying an estimated $3.66K and bringing the position to 153,886 shares worth $4.81M. The position accounts for 0.01% of the portfolio, ranked #721.

Woodline Partners first reported a position in GPCR in Q1 2023 and has held it in 15 quarters since. The position peaked at $14.6M in Q3 2024. 172 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Woodline Partners held 153,886 shares of Structure Therapeutics worth $4.81M as of Q3 2026.
  • Woodline Partners bought 78 Structure Therapeutics shares in Q3 2026, an estimated $3.66K.
  • Structure Therapeutics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #721 holding.
  • Woodline Partners first reported a position in Structure Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • Woodline Partners's Structure Therapeutics position peaked at $14.6M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.